Phase II umbrella study of novel anti-cancer agents in patients with NSCLC who progressed on an anti-PD-1/PD-L1 containing therapy - HUDSON

Study identifier:D6185C00001

ClinicalTrials.gov identifier:NCT03334617

EudraCT identifier:2017-002208-28

CTIS identifier:N/A

Recruiting

Official Title

An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients with Non-Small Cell Lung Cancer, who Progressed on an anti-PD-1/PD-L1 Containing Therapy (HUDSON).

Medical condition

Non-small Cell Lung Cancer

Phase

Phase 2

Healthy volunteers

No

Study drug

Durvalumab, Durvalumab, Durvalumab, Durvalumab, Durvalumab, Durvalumab, Durvalumab, AZD9150, AZD6738, Vistusertib, Olaparib, Oleclumab, trastuzumab deruxtecan, cediranib, AZD6738 (ceralasertib), AZD6738 (ceralasertib), AZD6738 (ceralasertib) (240 mg or 160 mg), AZD6738 (ceralasertib) 7 days monotherapy

Sex

All

Actual enrollment

570

Study type

Interventional

Age

18 Years - 99 Years

Date

Study Start Date: 18 Dec 2017
Estimated Primary Completion Date: 27 Feb 2025
Estimated Study Completion Date: 27 Feb 2025

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 May 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria